Concepedia

Author

Huub Jan Kleijn

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

H. Jan Kleijn, H. Kleijn, Huub J. Kleijn, Huub Jan Kleijn, Huub Kleijn

39

Publications

753

Citations

10

H-Index

27

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Certara (United States)Alexion Pharmaceuticals (United States)The Hague Centre for Strategic Studies
HJ

About

Huub Jan Kleijn is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and neuroscience.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

421

2

Pharmacology

2

2

421

3

Social Sciences

1

1

407

4

Neurology

1

1

407

5

Neuroscience

1

1

407

Huub Jan Kleijn

×

11

Publications

692

Citations

10

H-Index

YearCitations

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen,

Science Translational Medicine

2016

407

Population pharmacokinetic–pharmacodynamic analysis for sugammadex‐mediated reversal of rocuronium‐induced neuromuscular blockade

Huub Jan Kleijn, Daniel P. Zollinger, Michiel W. van den Heuvel,

British Journal of Clinical Pharmacology

2011

55

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

David Muccino, Alyn H. Morice, Surinder S. Birring,

ERJ Open Research

2020

53

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Chi‐Chung Li, Marissa F. Dockendorf, Ken Kowalski,

The Journal of Clinical Pharmacology

2017

41

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

Jonathan Monteleone, Xiang Gao, Huub Jan Kleijn,

Frontiers in Neurology

2021

32

Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent <i>Clostridium difficile</i> Infection

Ka Lai Yee, Huub Jan Kleijn, Thomas Kerbusch,

Antimicrobial Agents and Chemotherapy

2018

22

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Pratap Singh, Xiang Gao, Huub Jan Kleijn,

Frontiers in Neurology

2021

22

Pharmacokinetics and Pharmacodynamics of the <scp>BACE</scp>1 Inhibitor Verubecestat (<scp>MK</scp>‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study

K. Chris Min, Marissa F. Dockendorf, John Palcza,

Clinical Pharmacology & Therapeutics

2018

20

Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP

Eline M.T. van Maanen, Tamara J. van Steeg, Maurice J. Ahsman,

Journal of Pharmacology and Experimental Therapeutics

2018

16

Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling

Dhananjay Marathe, Petra M. Jauslin, Huub Jan Kleijn,

CPT Pharmacometrics & Systems Pharmacology

2023

14

Page 1